Table of Contents Table of Contents
Previous Page  323 / 916 Next Page
Show Menu
Previous Page 323 / 916 Next Page
Page Background

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S303–S364



Università degli Studi di Modena e Reggio Emilia, Dipartimento di

Scienze Biomediche- Metaboliche e Neuroscienze, Modena, Italy

Corresponding author.


Metabolic syndrome (MetS) is defined by metabo-

lic and cardio-vascular impairments and is frequently associated

with anxiety and depressive disorders. Both MetS and anxiety-

depressive syndromes feature similar systemic inflammatory

alterations. Inflammation of the large bowel is also a key factor

for the development of colorectal cancer (CRC).


To measure the prevalence of MetS and symptoms of

anxiety and depression among patients undergoing colonoscopy.


Cross-sectional study. Patients undergoing colonoscopy

aged 40 or more, with negative history for neoplasia or inflam-

matory bowel disease, were enrolled. Data collected: colonoscopy

outcome, presence/absence of MetS (IDF and ATP III criteria), pre-

sence/absence of depressive and anxiety symptoms assessed with



The sample was made up of 53 patients (female 24,

45.3%). Mean agewas 60.66


9.08. At least one adenomawas found

to 23 patients (43.3%). Prevalence of MetS ranged from 34% to 36%

(ATP III and IDF criteria, respectively). Prevalence of depressive and

anxiety symptoms was 20% and 33%, respectively.


Prevalence of MetS, anxiety and depressive symp-

toms among patients undergoing colonoscopy was higher than in

the general population.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Impact of anxiety-depressive

symptoms on outpatients’ quality of

life: Preliminary results from an

Italian observational study

S. Tassi


, G. Rioli

2 ,

, G. Mattei


, S. Ferrari


, G.M. Galeazzi



Università degli studi di modena e Reggio Emilia, Corso di Laurea in

Medicina e Chirurgia, Modena, Italy


Università degli Studi di Modena e Reggio Emilia, Scuola di

Specializzazione in Psichiatria, Sassuolo, Italy


Università degli Studi di Modena e Reggio Emilia, Scuola di

Specializzazione in Psichiatria, Modena, Italy


Università degli Studi di Modena e Reggio Emilia, Dipartimento di

Medicina Diagnostica- Clinica e di Sanità Pubblica- sezione di

Psichiatria, Modena, Italy

Corresponding author.


Several studies have shown an association between

the Short-Form36 (SF36) scores and anxiety-depressive symptoms,

suggesting that depression in particular could reduce Quality of

Life (QoL) to the same, and even greater, extent than chronic non-

communicable diseases, such as diabetes and hypertension.


To explore the relationship amongQoL and anxiety, depres-

sive and anxiety-depressive symptoms in an outpatient sample.


Cross-sectional study. Inclusion criteria: outpatients


40 years, without history for cancer, attending colono-

scopy after positive faecal occult blood test. Collected data: blood

pressure, blood glucose, lipid profile. Psychometric test: Hospital

Anxiety and Depression Scale (HADS). QoL was assessed with SF36.

Statistics performed with STATA13.


54 patients enrolled (27 females). Sixteen patients

(30.2%) were positive for anxiety symptoms, ten (18.9%) for depres-

sive symptoms and five (9.4%) for anxiety-depressive symptoms.

The perceived QoL was precarious in twelve subjects (22.2%): eight

(15.9%) had low score (

42) at “Mental Component Summary”

(MCS) subscale, three (5.7%) at the “Mental Health” item and one

patient (1.9%) at the “Vitality” one. At the multiple regression

analysis, depressive (OR = 28.63;


= 0.01) and anxiety-depressive

symptoms (OR = 11.16;


= 0.02) were associated with MCS.


The association emerging from the present study

between depressive/anxiety symptoms and the MCS component of

SF36 is consistent with available literature. Study design and small

sample size do not allow to generalize results, that need further

studies to be confirmed.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Prevalence, incidence and

comparative meta-analysis of

all-cause and specific-cause

cardiovascular disease in patients

with serious mental illness

M. Solmi

1 , 2 , 3 ,

, N. Veronese

2 , 4

, B. Beatrice

2 , 5

, R. Stella



S. Paolo


, G. Davide


, E. Collantoni


, G. Pigato


, A. Favaro



B. Stubbs

6 , 7

, A.F. Carvalho


, D. Vacampfort

9 , 10


C.U. Correll

11 , 12 , 13 , 14


University of Padua, Neuroscience Department, Padua, Italy


Institute for clinical Research and Education in Medicine,

Neuroscience Department, Padua, Italy


ULSS 17, Mental Health Department, Padua, Italy


University of Padua, Department of Medicine, Padua, Italy


ULSS 10, Mental Health Department, Portogruaro, Italy


South London and Maudsley NHS Foundation Trust, Physiotherapy

Department, London, United Kingdom


King’s College London, Health Service and Population Research

Department- Institute of Psychiatry, Psychology and Neuroscience,

London, United Kingdom


Faculty of Medicine, Federal University of Ceará, Departmend of

Clinical Medicine and Translational Psychiatry Research Group,

Fortaleza, Brazil


KU Leuven, Department of Rehabilitation Sciences, Leuven, Belgium


KU Leuven, University Psychiatric Center KU Leuven, Leuven,



The Zucker Hillside Hospital, Psychiatry Research, New York, USA


Albert Einstein College of Medicine, Medicine, New York, USA


The Feinstein Institute for Medical Research, Research, New York,



Hofstra Northwell School of Medicine, Medicine, New York, USA

Corresponding author.

Patients with severe mental illness (SMI) have been described at

higher risk of cardiovascular disease (CVD). The aimof this systema-

tic reviewandmeta-analysis was to quantify prevalence, incidence,

cross-sectional association and longitudinal increased risk of coro-

nary heart disease (CHD), stroke, transient ischemic attack and

cerebrovascular disease (CBVD), heart failure (HF), peripheral vas-

cular disease (PVD), death due to CVD, and any CVD in patients

with SMI. We included 92 studies, with a total population of

3,371,461 patients (BD = 241,226, MDD = 476,102, SCZ = 1,721,586,

SMI = 932,547) and 113,925,577 controls. Pooled prevalence of

any CVD in SMI was 9.9% (95% CI = 7.4–13.3) (33 studies, 360,144

patients). Compared to controls, after adjusting for a median of 7

confounders, SMI was associated with higher risk of CVD in cross-

sectional studies, OR:1.53 (95% CI = 1.27–1.83) (11 studies), with

CHD OR: 1.51 (95% CI = 1.47–1.55) (5 studies), with CBVD OR: 1.42

(95% CI = 1.21–1.66) (6 studies), and tended to be associatedwithHF

OR: 1.28 (95% CI = 0.99–1.65) (4 studies). Cumulative incidence was

3.6 CVD events in a median follow-up period of 8.4 years (range:

1.76–30). After considering a median of 6 confounders, SMI was

associated with higher longitudinal risk of CVD in longitudinal stu-

dies HR: 1.78 (95% CI = 1.6, 1.98) (31 studies), of CHD: HR: 1.54 (95%

CI 1.30–1.82) (18 studies), of CBVD HR: 1.64 (95% CI 1.26–2.14) (11

studies), of HF HR:2.10 (95% CI 1.64–2.70) (2 studies), of PVD, unad-

justed RR: 3.11 (95% CI 2.46–3.91) (3 studies), of death due to CVD,

HR 1.85 (95% CI 1.53–2.24) (16 studies). In this meta-analysis, the